171 related articles for article (PubMed ID: 12023395)
1. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy.
Scardino A; Gross DA; Alves P; Schultze JL; Graff-Dubois S; Faure O; Tourdot S; Chouaib S; Nadler LM; Lemonnier FA; Vonderheide RH; Cardoso AA; Kosmatopoulos K
J Immunol; 2002 Jun; 168(11):5900-6. PubMed ID: 12023395
[TBL] [Abstract][Full Text] [Related]
2. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
3. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy.
Graff-Dubois S; Faure O; Gross DA; Alves P; Scardino A; Chouaib S; Lemonnier FA; Kosmatopoulos K
J Immunol; 2002 Jul; 169(1):575-80. PubMed ID: 12077290
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
Gritzapis AD; Mahaira LG; Perez SA; Cacoullos NT; Papamichail M; Baxevanis CN
Cancer Res; 2006 May; 66(10):5452-60. PubMed ID: 16707474
[TBL] [Abstract][Full Text] [Related]
5. Identification of a potential human telomerase reverse transcriptase-derived, HLA-A1-restricted cytotoxic T-lymphocyte epitope.
Schreurs MW; Kueter EW; Scholten KB; Kramer D; Meijer CJ; Hooijberg E
Cancer Immunol Immunother; 2005 Jul; 54(7):703-12. PubMed ID: 15726360
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties.
Gritzapis AD; Voutsas IF; Lekka E; Tsavaris N; Missitzis I; Sotiropoulou P; Perez S; Papamichail M; Baxevanis CN
J Immunol; 2008 Jul; 181(1):146-54. PubMed ID: 18566379
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.
Lekka E; Gritzapis AD; Perez SA; Tsavaris N; Missitzis I; Mamalaki A; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2010 May; 59(5):715-27. PubMed ID: 19904532
[TBL] [Abstract][Full Text] [Related]
8. Identification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.
Scardino A; Alves P; Gross DA; Tourdot S; Graff-Dubois S; Angevin E; Firat H; Chouaib S; Lemonnier F; Nadler LM; Cardoso AA; Kosmatopoulos K
Eur J Immunol; 2001 Nov; 31(11):3261-70. PubMed ID: 11745343
[TBL] [Abstract][Full Text] [Related]
9. Characterization of HLA-A3-restricted cytotoxic T lymphocytes reactive against the widely expressed tumor antigen telomerase.
Vonderheide RH; Anderson KS; Hahn WC; Butler MO; Schultze JL; Nadler LM
Clin Cancer Res; 2001 Nov; 7(11):3343-8. PubMed ID: 11705846
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic HLA-B*0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses.
Adotévi O; Mollier K; Neuveut C; Cardinaud S; Boulanger E; Mignen B; Fridman WH; Zanetti M; Charneau P; Tartour E; Lemonnier F; Langlade-Demoyen P
Clin Cancer Res; 2006 May; 12(10):3158-67. PubMed ID: 16707616
[TBL] [Abstract][Full Text] [Related]
12. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Marukawa Y; Arai K; Yamashita T; Tsuji H; Kuzushima K; Takiguchi M; Kaneko S
Hepatology; 2006 Jun; 43(6):1284-94. PubMed ID: 16729333
[TBL] [Abstract][Full Text] [Related]
14. Lack of tumor recognition by hTERT peptide 540-548-specific CD8(+) T cells from melanoma patients reveals inefficient antigen processing.
Ayyoub M; Migliaccio M; Guillaume P; Liénard D; Cerottini JC; Romero P; Lévy F; Speiser DE; Valmori D
Eur J Immunol; 2001 Sep; 31(9):2642-51. PubMed ID: 11536162
[TBL] [Abstract][Full Text] [Related]
15. The HLA A*0201-restricted hTERT(540-548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor.
Purbhoo MA; Li Y; Sutton DH; Brewer JE; Gostick E; Bossi G; Laugel B; Moysey R; Baston E; Liddy N; Cameron B; Bennett AD; Ashfield R; Milicic A; Price DA; Classon BJ; Sewell AK; Jakobsen BK
Mol Cancer Ther; 2007 Jul; 6(7):2081-91. PubMed ID: 17620437
[TBL] [Abstract][Full Text] [Related]
16. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells.
Dupont J; Latouche JB; Ma C; Sadelain M
Cancer Res; 2005 Jun; 65(12):5417-27. PubMed ID: 15958591
[TBL] [Abstract][Full Text] [Related]
17. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
18. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes.
Arai J; Yasukawa M; Ohminami H; Kakimoto M; Hasegawa A; Fujita S
Blood; 2001 May; 97(9):2903-7. PubMed ID: 11313288
[TBL] [Abstract][Full Text] [Related]
19. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
20. A polyepitope DNA vaccine targeted to Her-2/ErbB-2 elicits a broad range of human and murine CTL effectors to protect against tumor challenge.
Scardino A; Alimandi M; Correale P; Smith SG; Bei R; Firat H; Cusi MG; Faure O; Graf-Dubois S; Cencioni G; Marrocco J; Chouaib S; Lemonnier FA; Jackson AM; Kosmatopoulos K
Cancer Res; 2007 Jul; 67(14):7028-36. PubMed ID: 17638916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
